Replies to post #307929 on NorthWest Biotherapeutics Inc (NWBO)

[H2theIzzo]

Here's a reply

[highwayman4life]

If you consider the source...it's probably because something stinks?

Only a quarter of newly diagnosed GBM patients survive for 24 months, and fewer than 10 percent of patients survive more than 5 years.

And we think this study is going to be a major contribution to the field in terms of data, and we certainly hope to be able to bring a new treatment option to patients.

Results: For the intent-to-treat (ITT ) population (n = 331), median OS (mOS) was 23.1 months from surgery. Because of the cross-over trial design, nearly 90% of the ITT population received DCVax-L. For patients with methylated MGMT (n = 131), mOS was 34.7 months from surgery, with a 3-year survival of 46.4%. As of this analysis, 223 patients are ≥ 30 months past their surgery date; 67 of these (30.0%) have lived ≥ 30 months and have a Kaplan-Meier (KM)-derived mOS of 46.5 months. 182 patients are ≥ 36 months past surgery; 44 of these (24.2%) have lived ≥ 36 months and have a KM-derived mOS of 88.2 months. A population of extended survivors (n = 100) with mOS of 40.5 months, not explained by known prognostic factors, will be analyzed further. Only 2.1% of ITT patients (n = 7) had a grade 3.

Long tail among?ITT populationWith immune-based therapies, a key focus is on the tail of the survival curve [26]. Among the ITT patients with a surgery date ≥ 30?months prior to the data collection (n = 223), 30% (n = 67) have lived ≥ 30? months, and their KM-derived mOS estimate is 46.5?months. Among the ITT patients with a surgery date ≥ 36?months prior to the data collection?(n = 182), 24.2% (n =?44)?have lived ≥ 36? months and their KM-derived mOS estimate is 88.2?months.

What a rug pull!!:-)

[Extremist223]

AF aint a sentinel more like a crow that entered the no fly zone.